Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors

Description

This clinical trial evaluates the safety and effectiveness of spatiotemporal stereotactic body radiation therapy (ST-SBRT) in treating patients with solid tumors that have spread to other parts of the body (polymetastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. ST-SBRT is designed to deliver radiation directly to the core of the tumor, while keeping the radiation exposure of the area around the tumor at minimal dosage.

Conditions

Metastatic Malignant Solid Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This clinical trial evaluates the safety and effectiveness of spatiotemporal stereotactic body radiation therapy (ST-SBRT) in treating patients with solid tumors that have spread to other parts of the body (polymetastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. ST-SBRT is designed to deliver radiation directly to the core of the tumor, while keeping the radiation exposure of the area around the tumor at minimal dosage.

A Pilot Study of Spatiotemporal SBRT for Poly-Metastatic Cancer

Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors

Condition
Metastatic Malignant Solid Neoplasm
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope Medical Center, Duarte, California, United States, 91010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Documented informed consent of the participant and/or legally authorized representative
  • * Assent, when appropriate, will be obtained per institutional guidelines
  • * Age: \>= 18 years
  • * Karnofsky performance status \> 60
  • * Poly-metastatic disease, \> 5 lesions, and with at least one lesion \> 2.0 cm, with limited treatment options, and ineligible for or in progression under the standard systemic therapy
  • * Pre-screening assessment confirms that the intervention can be administered without exceeding dose constraint guidelines
  • * Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and follow up magnetic resonance imaging (MRI) 3 months after treatment shows stable findings
  • * Spinal cord metastases are allowed as long as treatment with or without radiation is completed
  • * Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints
  • * Life expectancy \>= 3 months in the opinion of the treating investigators
  • * Off systemic therapy for at least one month prior and one month after study intervention
  • * Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements
  • * Those not eligible for SBRT after review by a radiation oncologist
  • * Serous medical comorbidities precluding radiotherapy
  • * Unable to undergo a CT scan
  • * Pregnant and/or breastfeeding women are excluded from this study as these agents may have the potential for teratogenic or abortifacient effects. Female patients of childbearing potentially must have a negative urine or serum pregnancy test within 72 hours prior to receiving therapy
  • * On active systemic therapy
  • * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

City of Hope Medical Center,

Yi-Jen Chen, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

2027-10-11